Cargando…

S71. CLINICAL, BEHAVIOURAL AND NEURAL VALIDATION OF THE POSITIVE AND NEGATIVE SYMPTOM SCALE (PANSS) AMOTIVATION FACTOR

BACKGROUND: Negative symptoms of schizophrenia are suggested to map onto two distinct factors – amotivation and diminished expression, which relate to different aspects of behaviour and neural activity. Most research in patients with schizophrenia is conducted with broad symptom assessment scales, s...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaliuzhna, Mariia, Kirschner, Matthias, Carruzzo, Fabien, Hartmann, Matthias, Martin, Bischof, Seifritz, Erich, Tobler, Philippe N, Kaiser, Stefan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7234253/
http://dx.doi.org/10.1093/schbul/sbaa031.137
_version_ 1783535722983063552
author Kaliuzhna, Mariia
Kirschner, Matthias
Carruzzo, Fabien
Hartmann, Matthias
Martin, Bischof
Seifritz, Erich
Tobler, Philippe N
Kaiser, Stefan
author_facet Kaliuzhna, Mariia
Kirschner, Matthias
Carruzzo, Fabien
Hartmann, Matthias
Martin, Bischof
Seifritz, Erich
Tobler, Philippe N
Kaiser, Stefan
author_sort Kaliuzhna, Mariia
collection PubMed
description BACKGROUND: Negative symptoms of schizophrenia are suggested to map onto two distinct factors – amotivation and diminished expression, which relate to different aspects of behaviour and neural activity. Most research in patients with schizophrenia is conducted with broad symptom assessment scales, such as the PANSS, for which factor solutions allowing the distinction between amotivation and diminished expression have only recently been reported. We aimed to establish whether the PANSS factor structure corresponds to the well-established two-factor structure of the Brief Negative Symptom Scale (BNSS) and whether it allows distinguishing specific behavioural and neuronal correlates of amotivation. METHODS: In study 1 (N=120) we examined the correlations between the PANSS factors and the BNSS factors. In study 2 (N=31) we examined whether PANSS amotivation is specifically associated with reduced willingness to work for reward in an effort-based decision making task. In study 3 (N=43) we investigated whether PANSS amotivation is specifically correlated with reduced ventral striatal activation during reward anticipation using functional magnetic resonance imaging. RESULTS: On the clinical level, the PANSS amotivation and diminished expression were highly correlated with their BNSS counterparts. On the behavioural level, PANSS amotivation factor but not the diminished expression factor was specifically associated with reduced willingness to invest effort to obtain a reward. On the neural level, PANSS amotivation was specifically associated with ventral striatal activation during reward anticipation. DISCUSSION: Our data confirm that the two domains of negative symptoms can be measured with the PANSS and are linked to specific aspects of behaviour and brain function. To our knowledge, this is the first study employing behavioural and neural measures to validate a new approach to clinical measurement of negative symptoms. Our results warrant a re-analysis of previous work that used the PANSS to further substantiate the distinction between the two factors in behavioural and neuroimaging studies.
format Online
Article
Text
id pubmed-7234253
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-72342532020-05-23 S71. CLINICAL, BEHAVIOURAL AND NEURAL VALIDATION OF THE POSITIVE AND NEGATIVE SYMPTOM SCALE (PANSS) AMOTIVATION FACTOR Kaliuzhna, Mariia Kirschner, Matthias Carruzzo, Fabien Hartmann, Matthias Martin, Bischof Seifritz, Erich Tobler, Philippe N Kaiser, Stefan Schizophr Bull Poster Session I BACKGROUND: Negative symptoms of schizophrenia are suggested to map onto two distinct factors – amotivation and diminished expression, which relate to different aspects of behaviour and neural activity. Most research in patients with schizophrenia is conducted with broad symptom assessment scales, such as the PANSS, for which factor solutions allowing the distinction between amotivation and diminished expression have only recently been reported. We aimed to establish whether the PANSS factor structure corresponds to the well-established two-factor structure of the Brief Negative Symptom Scale (BNSS) and whether it allows distinguishing specific behavioural and neuronal correlates of amotivation. METHODS: In study 1 (N=120) we examined the correlations between the PANSS factors and the BNSS factors. In study 2 (N=31) we examined whether PANSS amotivation is specifically associated with reduced willingness to work for reward in an effort-based decision making task. In study 3 (N=43) we investigated whether PANSS amotivation is specifically correlated with reduced ventral striatal activation during reward anticipation using functional magnetic resonance imaging. RESULTS: On the clinical level, the PANSS amotivation and diminished expression were highly correlated with their BNSS counterparts. On the behavioural level, PANSS amotivation factor but not the diminished expression factor was specifically associated with reduced willingness to invest effort to obtain a reward. On the neural level, PANSS amotivation was specifically associated with ventral striatal activation during reward anticipation. DISCUSSION: Our data confirm that the two domains of negative symptoms can be measured with the PANSS and are linked to specific aspects of behaviour and brain function. To our knowledge, this is the first study employing behavioural and neural measures to validate a new approach to clinical measurement of negative symptoms. Our results warrant a re-analysis of previous work that used the PANSS to further substantiate the distinction between the two factors in behavioural and neuroimaging studies. Oxford University Press 2020-05 2020-05-18 /pmc/articles/PMC7234253/ http://dx.doi.org/10.1093/schbul/sbaa031.137 Text en © The Author(s) 2020. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Poster Session I
Kaliuzhna, Mariia
Kirschner, Matthias
Carruzzo, Fabien
Hartmann, Matthias
Martin, Bischof
Seifritz, Erich
Tobler, Philippe N
Kaiser, Stefan
S71. CLINICAL, BEHAVIOURAL AND NEURAL VALIDATION OF THE POSITIVE AND NEGATIVE SYMPTOM SCALE (PANSS) AMOTIVATION FACTOR
title S71. CLINICAL, BEHAVIOURAL AND NEURAL VALIDATION OF THE POSITIVE AND NEGATIVE SYMPTOM SCALE (PANSS) AMOTIVATION FACTOR
title_full S71. CLINICAL, BEHAVIOURAL AND NEURAL VALIDATION OF THE POSITIVE AND NEGATIVE SYMPTOM SCALE (PANSS) AMOTIVATION FACTOR
title_fullStr S71. CLINICAL, BEHAVIOURAL AND NEURAL VALIDATION OF THE POSITIVE AND NEGATIVE SYMPTOM SCALE (PANSS) AMOTIVATION FACTOR
title_full_unstemmed S71. CLINICAL, BEHAVIOURAL AND NEURAL VALIDATION OF THE POSITIVE AND NEGATIVE SYMPTOM SCALE (PANSS) AMOTIVATION FACTOR
title_short S71. CLINICAL, BEHAVIOURAL AND NEURAL VALIDATION OF THE POSITIVE AND NEGATIVE SYMPTOM SCALE (PANSS) AMOTIVATION FACTOR
title_sort s71. clinical, behavioural and neural validation of the positive and negative symptom scale (panss) amotivation factor
topic Poster Session I
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7234253/
http://dx.doi.org/10.1093/schbul/sbaa031.137
work_keys_str_mv AT kaliuzhnamariia s71clinicalbehaviouralandneuralvalidationofthepositiveandnegativesymptomscalepanssamotivationfactor
AT kirschnermatthias s71clinicalbehaviouralandneuralvalidationofthepositiveandnegativesymptomscalepanssamotivationfactor
AT carruzzofabien s71clinicalbehaviouralandneuralvalidationofthepositiveandnegativesymptomscalepanssamotivationfactor
AT hartmannmatthias s71clinicalbehaviouralandneuralvalidationofthepositiveandnegativesymptomscalepanssamotivationfactor
AT martinbischof s71clinicalbehaviouralandneuralvalidationofthepositiveandnegativesymptomscalepanssamotivationfactor
AT seifritzerich s71clinicalbehaviouralandneuralvalidationofthepositiveandnegativesymptomscalepanssamotivationfactor
AT toblerphilippen s71clinicalbehaviouralandneuralvalidationofthepositiveandnegativesymptomscalepanssamotivationfactor
AT kaiserstefan s71clinicalbehaviouralandneuralvalidationofthepositiveandnegativesymptomscalepanssamotivationfactor